Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Akebia Therapeutics (AKBA) Short term Debt: 2018-2023

Historic Short term Debt for Akebia Therapeutics (AKBA) over the last 4 years, with Dec 2023 value amounting to $17.5 million.

  • Akebia Therapeutics' Short term Debt fell 45.31% to $17.5 million in Q4 2023 from the same period last year, while for Dec 2023 it was $17.5 million, marking a year-over-year decrease of 45.31%. This contributed to the annual value of $17.5 million for FY2023, which is 45.31% down from last year.
  • According to the latest figures from FY2023, Akebia Therapeutics' Short term Debt is $17.5 million, which was down 45.31% from $32.0 million recorded in FY2022.
  • Akebia Therapeutics' 5-year Short term Debt high stood at $97.5 million for FY2021, and its period low was $17.5 million during FY2023.
  • For the 3-year period, Akebia Therapeutics' Short term Debt averaged around $49.0 million, with its median value being $32.0 million (2022).
  • Data for Akebia Therapeutics' Short term Debt shows a maximum YoY tumbled of 67.19% (in 2022) over the last 5 years.
  • Yearly analysis of 3 years shows Akebia Therapeutics' Short term Debt stood at $97.5 million in 2021, then tumbled by 67.19% to $32.0 million in 2022, then crashed by 45.31% to $17.5 million in 2023.